🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Read the full article. brnw.ch/21wTiob

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study. Read full article. brnw.ch/21wTiGb

Ruminating over all the exciting #MultipleMyeloma data from #ASCO25, here are some of my thoughts on the long-term follow-up of CARTITUDE-1 trial (now published in Journal of Clinical Oncology) ascopubs.org/doi/10.1200/JC…

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

Long-Term Follow-Up of Real-World Adjuvant Anti-PD1 Checkpoint Inhibition and Targeted Therapy in Stage III Melanoma Patients. Read the full article. brnw.ch/21wTjJt

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) brnw.ch/21wTktH Jeff Sharman #leusm #lymsm

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory #MultipleMyeloma: Phase 3 IRAKLIA Study. Read the full article. brnw.ch/21wTlBD #MMSM

‼️ #EHA2025 #JCO simultaneous publication by Joshua Zeidner MD et al: Azacitidine, Venetoclax and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia: brnw.ch/21wTlXR

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Zipalertinib in Patients With EGFR Exon 20 Insertion-Positive NSCLC Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. Co-authored by Zosia Piotrowska Read full article. brnw.ch/21wTnp1

Huge congratulations to Joshua Zeidner MD on a stellar European Hematology Association presentation + first-author Journal of Clinical Oncology publication! The Aza/Ven/Revumenib triplet in newly diagnosed older/unfit NPM1m or KMT2Ar #AML delivered: 🧬 ORR 88% | CRc 81% | CR 67% 🔬 100% MRD-negative by flow 🚫 0%

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

We invite you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists through August 31, 2025. Learn more at brnw.ch/21wTrj7.

Acalabrutinib Plus Bendamustine-Rituximab in Untreated #MantleCellLymphoma. Read the full article. brnw.ch/21wTsUH

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. Co-authored by Joshua Zeidner MD. Read full article. brnw.ch/21wTv01

Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. Co-authored by Alex Gustafson and Nicholas Klemen. Read full article. brnw.ch/21wTvmj

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. brnw.ch/21wTwRe

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Co-authored by Jen Marvin-Peek, MD. Full article. brnw.ch/21wTx9F

Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial. Co-authored by Dr. Linda E. Carlson 🇨🇦 🇨🇦 Read full article. brnw.ch/21wTyvv